Tech Company Financing Transactions
Leucine Funding Round
Leucine, operating out of Wilmington, scored $7 million from Ecolab, Axilor Ventures and Pravega Ventures.
Transaction Overview
Company Name
Announced On
10/16/2023
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to refine its AI capabilities to make its AI Co-pilot a partner to production and quality managers on the shop floor, and expand its reach to more facilities and customers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2810 North Church Street
Wilmington, 19802
DE
Wilmington, 19802
DE
Phone
Undisclosed
Website
Email Address
Overview
Leucine is an AI-powered platform that helps pharmaceutical manufacturers in staying compliant and audit-ready while ensuring their medicines reach the patients faster. Using Leucine, Manufacturing, QA, and QC teams can significantly increase productivity and reduce deviations from cGMP guidelines across thousands of complex regulated workflows from material receipt to batch release. Leucine supports manufacturers across all modalities such as small molecules, biologics, gene therapies, vaccines etc.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Vivek Gera
Browse more venture capital transactions:
Prev: 10/16/2023: Xpanceo venture capital transaction
Next: 10/16/2023: Celestia Lab venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs